Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4.

Rheumatol Int. 2010 Jul;30(9):1183-9 Authors: Xu S, Lu H, Lin J, Chen Z, Jiang D Arachidonic acid metabolites, such as leukotriene B4 (LTB4), are known to play an important role in pathogenesis of rheumatoid arthritis (RA). Apart from leukocytes, RA synovial fibroblasts (RASF) produce a broad array of inflammatory mediators to recruit, retain and activate…

Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):62-8 Authors: D’Arena G, Taylor RP, Cascavilla N, Lindorfer MA Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have…

Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):599-602 Authors: Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM Discordant cytokine production is characteristic of chronic inflammatory conditions like rheumatoid arthritis (RA), and anti-cytokine therapeutics are becoming routinely used to treat RA in the clinic. Fibroblasts from rheumatoid synovium have been shown to contribute to cytokine…

Tumor necrosis factor-alpha inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways.

Mod Rheumatol. 2008;18(4):366-78 Authors: Okuma-Yoshioka C, Seto H, Kadono Y, Hikita A, Oshima Y, Kurosawa H, Nakamura K, Tanaka S We previously reported that synovial fibroblast-like cells (SFs) can be differentiated into chondrocytes through activin receptor-like kinase (ALK) 3 activation. The aim of this study was to clarify the effect and signaling pathways of tumor…

Multipotent mesenchymal stromal cells in articular diseases.

Best Pract Res Clin Rheumatol. 2008 Apr;22(2):269-84 Authors: Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noël D Although cartilage defects are common features of osteoarthritis and rheumatoid arthritis, current treatments can rarely restore the full function of native cartilage. Recent studies have provided new perspectives for cartilage engineering using multipotent mesenchymal stromal cells (MSC).…

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.

Eur J Pharmacol. 2008 Jun 24;588(1):93-8 Authors: Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J A new class of selective cyclooxygenase-2 (COX-2) inhibitors has been identified by high throughput screening. Structurally distinct from previously described selective COX-2 inhibitors, these benzopyrans contain a carboxylic acid function…

Effects of a tetramethoxyhydroxyflavone p7f on the expression of inflammatory mediators in LPS-treated human synovial fibroblast and macrophage cells.

J Microbiol Biotechnol. 2008 Apr;18(4):686-94 Authors: Yoon DY, Cho MC, Kim JH, Kim EJ, Kang JW, Seo EH, Shim JH, Kim SH, Lee HG, Oh GT, Hong JT, Park JW, Kim JW The inhibitory effects of 5,6,3′,5′-tetramethoxy 7,4′-hydroxyflavone (labeled as p7F) were elucidated on the productions of proinflammatory cytokines as well as inflammatory mediators in…

Technology insight: adult mesenchymal stem cells for osteoarthritis therapy.

Nat Clin Pract Rheumatol. 2008 Jul;4(7):371-80 Authors: Nöth U, Steinert AF, Tuan RS Despite the high prevalence and morbidity of osteoarthritis (OA), an effective treatment for this disease is currently lacking. Restoration of the diseased articular cartilage in patients with OA is, therefore, a challenge of considerable appeal to researchers and clinicians. Techniques that cause…